SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift gets nod for proposed scheme of amalgamation

18 Nov 2011 Evaluate

Ind-Swift has received an approval for the proposed scheme of amalgamation of Essix Biosciences and Dashmesh Medicare with itself. The board at its meeting held on November 14, 2011 has granted its in-principle approval for the same.

The amalgamation will be done under section 391 to 394 of the Companies Act, 1956, subject to appropriate statutory and regulatory approvals.

Essix Biosciences and Dashmesh Medicare are both unlisted entities.

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×